Michael A. Mussallem - Nov 3, 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Director
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
Nov 3, 2023
Transactions value $
-$893,121
Form type
4
Date filed
11/6/2023, 06:33 PM
Previous filing
Oct 2, 2023
Next filing
Dec 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $1.08M +29.4K +654.28% $36.75 33.8K Nov 3, 2023 Direct F1
transaction EW Common Stock Sale -$1.97M -29.4K -86.74% $67.18 4.49K Nov 3, 2023 Direct F1, F2
transaction EW Common Stock Gift $0 -372K -100% $0.00* 0 Nov 6, 2023 401(k) F3
transaction EW Common Stock Gift $0 +372K +10.14% $0.00 4.04M Nov 6, 2023 By Living Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -29.4K -14.29% $0.00 176K Nov 3, 2023 Common Stock 29.4K $36.75 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $66.59 to $67.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3 In connection with an in-kind transfer of shares from the Reporting Person's 401(k) account to his Living Trust, the remaining 0.7321 of one share was automatically sold by the 401(k) plan administrator at a price of $63.505269 per share, for a total of $46.50, to comply with the plan administrator's policy prohibiting the transfer of a fractional share.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.